Mersana Therapeutics (MRSN) Set to Announce Quarterly Earnings on Wednesday

Mersana Therapeutics (NASDAQ:MRSN) is scheduled to post its quarterly earnings results before the market opens on Wednesday, November 13th. Analysts expect Mersana Therapeutics to post earnings of ($0.18) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Mersana Therapeutics (NASDAQ:MRSN) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). Mersana Therapeutics had a negative return on equity of 333.91% and a negative net margin of 349.98%. The firm had revenue of $2.30 million for the quarter, compared to the consensus estimate of $8.72 million. During the same period in the previous year, the company posted ($0.47) EPS. Mersana Therapeutics’s quarterly revenue was down 78.3% compared to the same quarter last year. On average, analysts expect Mersana Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mersana Therapeutics Stock Down 1.6 %

NASDAQ:MRSN opened at $2.53 on Tuesday. The company has a debt-to-equity ratio of 2.02, a current ratio of 2.72 and a quick ratio of 2.72. Mersana Therapeutics has a 1-year low of $1.15 and a 1-year high of $6.28. The company has a 50-day moving average of $1.95 and a 200 day moving average of $2.07. The firm has a market cap of $310.38 million, a PE ratio of -2.91 and a beta of 1.50.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on MRSN shares. Citigroup dropped their price objective on shares of Mersana Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, August 27th. Robert W. Baird reduced their price target on Mersana Therapeutics from $4.00 to $3.00 and set a “neutral” rating for the company in a research report on Wednesday, August 14th. Finally, Lifesci Capital raised Mersana Therapeutics to a “strong-buy” rating in a research report on Monday, July 29th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Mersana Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $6.00.

Insiders Place Their Bets

In related news, CEO Martin H. Jr. Huber sold 50,423 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $1.76, for a total value of $88,744.48. Following the completion of the transaction, the chief executive officer now directly owns 116,327 shares of the company’s stock, valued at $204,735.52. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 70,849 shares of company stock valued at $129,184. 11.80% of the stock is currently owned by corporate insiders.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.